BUZZ-Akero Therapeutics rises after Citi initiates with 'buy' rating

Reuters11-19

BUZZ-<a href="https://laohu8.com/S/AKRO">Akero Therapeutics</a> rises after Citi initiates with 'buy' rating

** Drug developer Akero Therapeutics' AKRO.O shares rise ~2.5% to $28.78

** Citi initiates coverage of AKRO with "buy" rating

** Brokerage says AKRO is developing efruxifermin, a novel FGF21 agonist, for treating metabolic dysfunction-associated steatohepatitis (MASH)

** MASH causes an excessive accumulation of fat in the liver

** "Efruxifermin is well-positioned to differentiate in this difficult-to-treat population given its potential best-in-disease efficacy," says Citi

** Brokerage sets PT at $65, a ~131.4% upside on stock's last close

** Ten of 11 brokerages rate the stock "buy" or higher, 1 "hold"; their median PT is $46 - LSEG data

** Including session's moves, stock up ~22.23% YTD

(Reporting by Prakhar Srivastava in Bengaluru)

((Prakhar.srivastava2@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484169677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-19 00:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484169677","market":"us","top_or_hot":-1,"title":"BUZZ-Akero Therapeutics rises after Citi initiates with 'buy' rating","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> rises after Citi initiates with 'buy' rating</title></head><body><p>** Drug developer Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' <span>AKRO.O</span> shares rise ~2.5% to $28.78</p><p>** Citi initiates coverage of AKRO with \"buy\" rating</p><p>** Brokerage says AKRO is developing efruxifermin, a novel FGF21 agonist, for <span>treating </span>metabolic dysfunction-associated steatohepatitis (MASH)</p><p>** MASH <span>causes</span> an excessive accumulation of fat in the liver</p><p>** \"Efruxifermin is well-positioned to differentiate in this difficult-to-treat population given its potential best-in-disease efficacy<span>,</span>\" says Citi</p><p>** Brokerage sets PT at $65, a ~131.4% upside on stock's last close</p><p>** Ten of 11 brokerages rate the stock \"buy\" or higher, 1 \"hold\"; their median PT is $46 - LSEG data</p><p>** <span>Including session's moves</span>, stock up ~22.23% YTD</p><p> (Reporting by Prakhar Srivastava in Bengaluru)</p><p> ((Prakhar.srivastava2@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Akero Therapeutics rises after Citi initiates with 'buy' rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Akero Therapeutics rises after Citi initiates with 'buy' rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 00:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4N3MP14G:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Akero Therapeutics rises after Citi initiates with 'buy' rating** Drug developer Akero Therapeutics' AKRO.O shares rise ~2.5% to $28.78** Citi initiates coverage of AKRO with \"buy\" rating** ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4N3MP14G:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKRO","symbol_name":"Akero Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4N3MP14G:1","article_id":"2484169677","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484169677","pubTimestamp":1731945676,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Akero Therapeutics rises after Citi initiates with 'buy' rating** Drug developer Akero Therapeutics' AKRO.O shares rise ~2.5% to $28.78** Citi initiates coverage of AKRO with \"buy\" rating** Broke","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"AKRO":"Akero Therapeutics"},"translate_title":"花旗给予“买入”评级后，Akero Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":0.9},"content_text":"BUZZ-Akero Therapeutics rises after Citi initiates with 'buy' rating** Drug developer Akero Therapeutics' AKRO.O shares rise ~2.5% to $28.78** Citi initiates coverage of AKRO with \"buy\" rating** Brokerage says AKRO is developing efruxifermin, a novel FGF21 agonist, for treating metabolic dysfunction-associated steatohepatitis (MASH)** MASH causes an excessive accumulation of fat in the liver** \"Efruxifermin is well-positioned to differentiate in this difficult-to-treat population given its potential best-in-disease efficacy,\" says Citi** Brokerage sets PT at $65, a ~131.4% upside on stock's last close** Ten of 11 brokerages rate the stock \"buy\" or higher, 1 \"hold\"; their median PT is $46 - LSEG data** Including session's moves, stock up ~22.23% YTD (Reporting by Prakhar Srivastava in Bengaluru) ((Prakhar.srivastava2@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484169677"}